Joseph Philip Zucchi

Featured in: Favicon

msn.com

doximity.com Favicon

opmed.doximity.com

Articles

6 Tips for Meniscal Root Tear Repair

Sep 3, 2024 | opmed.doximity.com | Brian B Gilmer |Richard Allen |Joseph Philip Zucchi |Danny Landau

Despite being initially described in 1991, when I exited training about 10 years ago, I had never seen, much less treated, a meniscal root tear. However, I am now certain that it was seeing me. What seemed like a relatively rare or obscure diagnosis is now one of the most commonly performed isolated meniscal repairs in my practice. Unfortunately, recognition outside of the sports medicine and arthroscopic knee subspecialty remains lagging and these tears are often missed or present late.
The Cost of a Non-Compete? Your Health

Sep 3, 2024 | opmed.doximity.com | Richard Allen |Brian B Gilmer |Joseph Philip Zucchi |Danny Landau

Something great has happened. The Federal Trade Commission (FTC) struck down the practice of most non-compete clauses in employment contracts. I believe that this is wonderful news and a long time coming, but many may not like this ruling. I think it really depends upon which side of the fence you are on — are you an employer who wants to keep your employees under your thumb, or are you an employee who would like freedom? I think it is obvious from the phrasing of that question which side I am on.
The Expanding Universe of GLP-1 Medications: A Revolution Beyond Diabetes and Weight Loss

Sep 3, 2024 | opmed.doximity.com | Joseph Philip Zucchi |Richard Allen |Brian B Gilmer |Danny Landau

Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for glycemic control in Type 2 diabetes and later approved for obesity, have embarked on a remarkable journey of therapeutic expansion. Medications such as semaglutide and tirzepatide are now revealing their versatility in addressing a diverse range of complex health conditions, offering a beacon of hope for improved chronic disease management and patient outcomes.
The Real Weight of Misunderstanding Obesity

Jul 14, 2024 | msn.com | Joseph Philip Zucchi

Continue reading More for You Continue reading More for You
Top 10 of the Most and Least Frugal Things This Doctor Does

Apr 9, 2024 | opmed.doximity.com | Jordan Frey |Lauren Grawert |Joseph Philip Zucchi

As a personal finance expert, I often have people tell me that they think I’m very frugal … like very, very frugal. But I actually don’t think that I am. Believe it or not, I have a healthy balance between the frugal and non-frugal things that I do. Below, I share the 10 most and least frugal things that I do. (And for the record, it’s really not the frugal things that I do, but the frugal things that my wife Selenid and I do.
The Pelvic Floor Is Often Ignored

Apr 9, 2024 | opmed.doximity.com | Lauren Grawert |Joseph Philip Zucchi |Melissa Schiffman

She’s the reason I pee when I sneeze. She’s the reason I fart when I walk. And yet, I would give birth to my daughter again, a thousand times over. And that, I think, is the crux of the cross we bear as mothers — the bearing of children and, specifically, bearing down. As a resident, I attended the Pelvic Floor Symposiums held by my institution. They were fascinating discussions led by mostly surgeons who were women, but these symposia were completely ignored by most other surgeons.
Why Aren't Pharmacies Filling My Patient's Life-Saving Medication?

Apr 8, 2024 | opmed.doximity.com | Lauren Grawert |Joseph Philip Zucchi |Melissa Schiffman |Alexander T. Yahanda

I sat on the phone yesterday consoling a single mother going through heroin withdrawal. In between bouts of vomiting and dry heaving, she pleaded, “When will I be able to pick up the medication you ordered that stops all of this?” This mother had already overcome significant barriers Americans face when seeking addiction treatment, including stigma associated with treatment, affordability of treatment, and finding high quality, highly trained addiction specialists.
The Dangers of Compounded Obesity Medications

Apr 8, 2024 | opmed.doximity.com | Joseph Philip Zucchi |Melissa Schiffman |Alexander T. Yahanda

As a society, we stand on the brink of a revolution in treating obesity, a condition affecting millions and a leading cause of numerous health problems worldwide. The recent surge in the popularity of GLP-1 agonists, like semaglutide (Wegovy) and tirzepatide (Zepbound), has been a beacon of hope, showcasing significant weight loss and health improvements.